Search research articles
Contact Us
Filters
Showing results (41-50 of 128) with videos related to
Page
of 13
Sort By:
Endocrine-Related Cancer
|
December 3, 2005
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer
Davide Melisi, Rosa Caputo, Vincenzo Damiano, et al.
The Journal of Biological Chemistry
|
August 9, 2022
p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells
Silvia Pietrobono, Raffaella De Paolo, Domenico Mangiameli, et al.
Expert Opinion on Therapeutic Targets
|
August 9, 2011
Emerging pathways and future targets for the molecular therapy of pancreatic cancer
Vanja Vaccaro, Davide Melisi, Emilio Bria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2009
Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity
Davide Melisi, Valeria Ossovskaya, Cihui Zhu, et al.
Molecular Cancer Therapeutics
|
September 29, 2019
Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
Raffaela Santoro, Marco Zanotto, Francesca Simionato, et al.
BMC Cancer
|
March 17, 2018
The curious case of Gαs gain-of-function in neoplasia
Giulio Innamorati, Thomas M Wilkie, Havish S Kantheti, et al.
Cancer Discovery
|
November 21, 2020
Clinicogenomic Analysis of <i>FGFR2</i>-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M Silverman, Antoine Hollebecque, Luc Friboulet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2011
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers
Roberta Rosa, Davide Melisi, Vincenzo Damiano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2003
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect
Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, et al.
Cancer Chemotherapy and Pharmacology
|
September 5, 2019
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer
Ivelina Gueorguieva, Josep Tabernero, Davide Melisi, et al.
Page
of 13
Search research articles
Search
Showing results (41-50 of 128) with videos related to
Sort By:
Page
of 13
Endocrine-Related Cancer
|
December 3, 2005
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer
Davide Melisi, Rosa Caputo, Vincenzo Damiano, et al.
The Journal of Biological Chemistry
|
August 9, 2022
p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells
Silvia Pietrobono, Raffaella De Paolo, Domenico Mangiameli, et al.
Expert Opinion on Therapeutic Targets
|
August 9, 2011
Emerging pathways and future targets for the molecular therapy of pancreatic cancer
Vanja Vaccaro, Davide Melisi, Emilio Bria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2009
Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity
Davide Melisi, Valeria Ossovskaya, Cihui Zhu, et al.
Molecular Cancer Therapeutics
|
September 29, 2019
Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
Raffaela Santoro, Marco Zanotto, Francesca Simionato, et al.
BMC Cancer
|
March 17, 2018
The curious case of Gαs gain-of-function in neoplasia
Giulio Innamorati, Thomas M Wilkie, Havish S Kantheti, et al.
Cancer Discovery
|
November 21, 2020
Clinicogenomic Analysis of <i>FGFR2</i>-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M Silverman, Antoine Hollebecque, Luc Friboulet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2011
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers
Roberta Rosa, Davide Melisi, Vincenzo Damiano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2003
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect
Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, et al.
Cancer Chemotherapy and Pharmacology
|
September 5, 2019
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer
Ivelina Gueorguieva, Josep Tabernero, Davide Melisi, et al.
Page
of 13